Christine Blank, Contributing Editor
Novel drug approved for Huntington's symptom
FDA recently approved deutetrabenazine (Austedo, Teva Pharmaceuticals) to treat chorea associated with Huntington’s disease (HD). The medication is only the second product approved to treat HD, and is the first deuterated product approved by FDA.
Hep C drugs approved for kids
FDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Pharmacists Are Central to Supervalu Diabetes Campaign
Supervalu’s diabetes campaign offers risk assessments, screening, and food education.
Study: New Diabetes Drug Class Reduces Heart Deaths
New class of glucose-lowering agents lowers hospitalization and death rates even in Type 2 patients without heart disease.
Major EpiPen recall issued
Meridian Medical Technologies, Mylan's manufacturing partner for the EpiPen Auto-Injector, expanded a voluntary recall of the EpiPen and EpiPen Jr. epinephrine auto-Injectors to now include additional lots distributed in the United States and other markets.
First progressive MS drug carries high price tag
While FDA just approved the first drug for primary progressive multiple sclerosis (PPMS), the drug’s price tag is controversial.
First drug for rare skin cancer wins approval
FDA approved the first treatment for metastatic Merkel cell carcinoma (MCC), a rare, aggressive skin cancer.
New Parkinson's drug, 2 others approved
FDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
CVS Generic Drugs Suit Fails to Get Class Action
California judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients.
FDA Approves 800 Generics in 2016, but Legislators Think Process Should Be Faster
FDA set a record for generics approval, but is the process still too cumbersome?